サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：心臓修復システムの世界市場-2022-2029
市場調査レポート
商品コード
1217589

心臓修復システムの世界市場-2022-2029

Global Cardiac Restoration Systems Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
心臓修復システムの世界市場-2022-2029
出版日: 2023年02月14日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

心臓修復システムの世界市場規模は、予測期間（2022-2029年）に健全なCAGRで成長すると予測されています。

心臓修復システムは、損傷や病気の心臓弁を治療するために採用されています。CVDは心臓や血管に影響を与え、冠動脈疾患や脳卒中などの症状を悪化させ、リスクの高い血栓や動脈内の脂肪沈着などを引き起こします。心臓修復システムは、心室を改造し、外科的前心室内修復術（SAVER）を開始する任意の冠動脈バイパス移植の後に使用されます。

市場力学

心臓疾患の増加、老年人口、市場開拓、肥満人口が世界の心臓修復システム市場を後押ししています。

心血管疾患の患者数の増加が、世界の心臓修復システム市場の成長を後押ししています。

心血管疾患には、冠状動脈性心臓疾患、脳血管疾患、リウマチ性心臓疾患など、心臓や血管の病気が含まれます。CVDの症例が増加していることが、世界の心臓修復システム市場を牽引しています。例えば、米国心臓協会によると、2020年に世界でおよそ1910万人の死亡がCVDによって引き起こされました。世界的には、2020年に約2億4,410万人が虚血性心疾患（IHD）と共に生活し、女性よりも男性に多く（それぞれ1億4,100万人と1億310万人）見られると評価されました。また、WHOによると、心血管疾患（CVD）は世界の主要な死因であり、年間1790万人が死亡していると推定されています。

心臓病や脳卒中の最も重要な行動的危険要素は、不健康な食事、身体的怠惰、タバコの使用、有害なアルコールの使用です。行動学的危険因子の影響は、血圧の上昇、血糖値の上昇、血中脂質の増加、過体重や肥満として患者に現れることがあります。行動学的危険因子の増加は、世界的にCVDの増加につながります。米国心臓協会の2022年心臓病・脳卒中統計更新ファクトシートGlobal Burden of Diseaseによると、タバコ（喫煙、副流煙、噛みタバコを含む）は2020年に世界で推定810万人（男性630万人、女性180万人）の死亡の原因となっていることが分かっています。また、2020年のデータに基づくと、高体重指数に起因する年齢標準化死亡率は、高所得のアジア太平洋地域で最も低く、オセアニア、北アフリカ、中東、中央アジア、サブサハラアフリカ南部、中・東欧、中央サブサハラアフリカ、中南米の場所で最も高くなっています。高BMIは、2020年の世界の死亡者数240万人の原因となっています。

同様に、PAHOによると、世界的にアルコール消費は毎年300万人の死亡の原因となり、数百万人が健康を失っています。アルコールの消費は、肝臓疾患、交通事故、暴力、数種類のがん、心血管疾患、自殺、結核、HIV/AIDSなど、200以上の健康状態に因果関係があるとされています。したがって、前述のデータは、行動の危険因子の増加は、心血管疾患の上昇につながっていることを示し、それによって予測期間中の世界の心臓修復システムの成長を後押ししています。

心臓手術の高コストが、世界の心臓修復システム市場の成長を阻害します。

しかし、心臓手術の高コストが、予測期間中の世界の心臓修復システム市場の成長を抑制しています。例えば、インドにおける三尖弁修復手術の平均費用は約3900USドルです。

COVID-19の影響分析

Journal of Thoracic Disease誌が2021年1月に発表したCOVID-19発生時の心臓外科診療：地域全体の調査論文によると、すべての医療センターが患者や職員のスクリーニングのための特定のプロトコルを採用しました。集中治療室（ICU）専用ベッドが約30.0％、心臓手術室が約22.2％と大幅に減少し、麻酔科医5.8％、灌流士5.6％、看護師4.8％と、他科への人員再配置が明らかになりました。心臓外科医が他の業務に配置転換されることはありません。世界的には、施設や外科医がガイドラインに従って緊急性のない手術を抑制したため、成人の心臓手術の症例数が劇的に減少し、2019年の667件以上に対し、2020年には335件となったことが確認されました。したがって、心臓手術の減少と緊急の医療要件へのリソースの移転は、市場の成長を妨げ、世界の心臓修復システム市場にマイナスの影響を与えました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 市場イベント
      • 心血管疾患患者数の増加
    • 抑制要因
      • 心臓外科手術の高コスト
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • 僧帽弁修復システム
  • 左心室修復システム

第8章 エンドユーザー別

  • 病院
  • 専門クリニック
  • ASC

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第10章 製品タイプ別市場規模分析と前年比成長率分析（%）（英語

第11章 市場規模分析とYoY成長率分析（%）：エンドユーザー別

第12章 競合環境競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第13章 企業プロファイル

  • Medtronic Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Abbott
  • BioVentrix Inc
  • NeoChord Inc
  • Edwards Lifesciences Corp
  • Virbac
  • Micro Port Scientific Corporation
  • CryoLife Inc.
  • Xeltis AG
  • Cook Medical

第14章 DataM

目次
Product Code: DMMD1800

Market Overview

The global cardiac restoration systems size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Cardiac restoration systems are employed for treating damaged and diseased heart valves. CVDs affect the heart and blood vessels, escalating conditions such as coronary heart diseases, stroke, etc., causing high-risk blood clots and fatty depositions in arteries. Cardiac restoration systems are used after any coronary artery bypass grafting remodeling the ventricular and initiating surgical anterior ventricular endocardial restoration (SAVER).

Market Dynamics

The growing number of cardiac diseases, geriatric population, market developments, and obese population is boosting the global cardiac restoration systems market.

The increasing number of cardiovascular disease cases is fueling the growth of the global cardiac restoration systems market.

Cardiovascular diseases include heart and blood vessel ailments, including coronary heart disorder, cerebrovascular disease, rheumatic heart disease, and other conditions. The growing cases of CVD are driving the global cardiac restoration systems. For instance, according to the American Heart Association, roughly 19.1 million deaths were caused by CVD globally in 2020. Globally, it was assessed that about 244.1 million individuals were living with ischemic heart disease (IHD), and it was more prevalent in males than in females (141.0 and 103.1 million people, respectively) in 2020. Also, according to the WHO, Cardiovascular diseases (CVDs) are the major cause of death worldwide, causing an estimated 17.9 million deaths annually.

The most important behavioral risk elements of heart disease and stroke are an unhealthful diet, physical laziness, tobacco use, and the harmful use of alcohol. The effects of behavioral risk factors may appear in patients as increased blood pressure, boosted blood glucose, extended blood lipids, and overweight and obesity. The upsurge in behavioral risk factors leads to increased CVDs globally. According to the American Heart Association's 2022 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease, Tobacco (including smoking, secondhand smoke, and chewing tobacco) caused an estimated 8.1 million deaths globally in 2020 (6.3 million men and 1.8 million women). Also, based on 2020 data, age-standardized mortality rates attributable to high body mass index were lowest in high-income Asia Pacific and highest in Oceania, North Africa, the Middle East, Central Asia, southern sub-Saharan Africa, and locations in Central and Eastern Europe, Central sub-Saharan Africa, and Central Latin America. High BMI was attributed to 2.40 million global deaths in 2020.

Likewise, according to PAHO, globally, alcohol consumption contributes to 3 million deaths each year, and several millions of people lose health. The consumption of alcohol is causally linked to over 200 health conditions, including liver diseases, road injuries, violence, several types of cancers, cardiovascular diseases, suicides, tuberculosis, and HIV/AIDS. Thus, the mentioned data indicates that the increase in behavioral risk factors is leading to rising in cardiovascular diseases, thereby boosting the global cardiac restoration systems market growth in the forecast period.

The high cost of cardiac surgery will hamper the global cardiac restoration systems market growth.

However, the high cost of cardiac surgery is restraining the global cardiac restoration systems market during the forecast period. For example, the average tricuspid valve repair surgery cost in India is about 3900 USD.

COVID-19 Impact Analysis

According to a Cardiac surgery practice during the COVID-19 outbreak: a regionwide survey article published in January 2021 by the Journal of Thoracic Disease, all healthcare centers adopted specific protocols for screening patients and personnel. A significant reduction in the number of dedicated intensive care unit (ICU) beds was reduced by around 30.0%, and cardiac operating rooms were reduced by approximately 22.2%along with personnel relocation to other departments was disclosed such as anesthesiologists by 5.8%, perfusionists by 5.6%, and nurses by 4.8% among others. Cardiac surgeons were never reallocated to other services. Globally, we witnessed dramatically lower adult cardiac surgery case volumes, with 335 procedures in 2020 compared to over 667 procedures in 2019, as institutions and surgeons followed guidelines to curtail non-urgent operations. Thus, the reduction in cardiac procedures and relocation of resources toward urgent healthcare requirements hampered the market growth, negatively impacting the global cardiac restoration system market.

Segment Analysis

Mitral valve restoration systems are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

The prevalence of rheumatic heart disease, the most common valvular heart disease (affecting approximately 41 million people), has been rising in developing nations, likely due to the expansion of the young adult population and the decrease in premature mortality that has resulted from improved access to antibiotics, microbiological testing, and echocardiography. Mitral regurgitation affects 24 million people worldwide, with great variability between and among nations. Primary mitral regurgitation arises due to myxomatous degeneration and mitral valve prolapse, largely due to genetic predispositions, while secondary mitral regurgitation accounts for 65% of cases and arises secondary to dilation and heart failure. MR is either equally prevalent between the sexes or slightly more prevalent in men than women. Mitral valve prolapse rates (MVP) are considerably higher in white patients than in black patients. MVP is the most common cardiac mitral valvular pathology worldwide, accounting for 2% to 3% of the total population. RHD remains prevalent in developing countries and is the most common cause of mitral valvular pathology resulting in hospital admissions. Acute MR can present with sudden onset of dyspnea and flash pulmonary edema, frequently secondary to myocardial infarction.

Chronic MR is often asymptomatic, though treatment is recommended before symptom onset. Furthermore, developments such as the first beating heart mitral valve repair on the West Coast were performed by Tom C. Nguyen, MD, chief of UC San Francisco's Division of Adult Cardiothoracic Surgery, and his surgical team in September 2021. The HARPOON™ Beating Heart Mitral Valve Repair System was used for the procedure as part of the RESTORE clinical trial. Thus, the mentioned data indicates that the mitral valve restoration systems will dominate the global cardiac restoration system in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

North America is estimated to hold a large market over the forecast period (2022-2029) because of the growing cases of cardiovascular conditions and the existence of key market players in this region. For instance, according to the CDC, a U.S. American dies every 34 seconds because of cardiovascular disease. Cardiovascular disease caused over 697,000 deaths in 2020. Moreover, the existence of key market players such as Abbott, BioVentrix Inc., CryoLife Inc., Edwards Lifesciences Corp, NeoChord Inc. among more, holding most of the global market, endure the growth of North America's cardiac restoration system market at a high CAGR throughout the forecast period. For instance, in March 2020, BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, reported that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has united with the European REVIVE-HF clinical trial of the Revivent TC Transcatheter Ventricular Enhancement System as co-principal investigator. Also, in January 2022, BioVentrix, Inc., a privately held medical device corporation concentrated on less intrusive treatments to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), acquired MateraCor, Inc., a firm focused on preventing the advancement of, and reversing, heart failure through the use of injectable alginate-based hydrogel.

Likewise, in February 2020, CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, was granted CE Mark for its On-X Ascending Aortic Prosthesis (AAP) indicated for the treatment of diseased, damaged, or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm, permitting it to resume dispersal in the European Union. Moreover, in September 2022, Edwards Lifesciences Corporation received FDA approval for its PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in treating patients with degenerative mitral regurgitation (DMR). Thus, the data mentioned indicate that North America's market will grow at a high CAGR throughout the forecasted period.

Competitive Landscape

The growing focus on innovation keeps the global cardiac restoration systems market competitive. Abbott, BioVentrix Inc., NeoChord Inc., Edwards Lifesciences Corp, Virbac, Medtronic Inc., Micro Port Scientific Corporation, CryoLife Inc., Xeltis AG, and Cook Medical are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in March 2022, Edwards Lifesciences received permission from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a tissue valve replacement designed for the heart's mitral position.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. has CG Future Annuloplasty Ring and Band: The CG Future is an annuloplasty system for mitral valve repair, developed to predictably renovate the annulus to keep the apposition of the anterior and posterior leaflets.

The global cardiac restoration systems market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Events
      • 4.1.1.2. Increasing Number of Cardiovascular Disease Cases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost Of Cardiac Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Mitral Valve Restoration Systems *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Left Ventricular Restoration Systems

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. ASCs

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics

10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Medtronic Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott
  • 13.3. BioVentrix Inc
  • 13.4. NeoChord Inc
  • 13.5. Edwards Lifesciences Corp
  • 13.6. Virbac
  • 13.7. Micro Port Scientific Corporation
  • 13.8. CryoLife Inc.
  • 13.9. Xeltis AG
  • 13.10. Cook Medical

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us